Montana legislation · 2025 Regular Session
Montana SJ33: Interim study of the prescription drug supply chain
Status: Passed one chamber, May 5, 2025
What the bill says
A joint resolution of the senate and the house of representatives of the state of montana requesting an interim study on the entities within the prescription drug supply chain, pharmacy sustainability, and the impacts on affordability and patient access; and requiring that the final results of the study be reported to the 70th legislature. now, therefore.
From the engrossed text:
A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA REQUESTING AN INTERIM STUDY ON THE ENTITIES WITHIN THE PRESCRIPTION DRUG SUPPLY CHAIN, PHARMACY SUSTAINABILITY, AND THE IMPACTS ON AFFORDABILITY AND PATIENT ACCESS; AND REQUIRING THAT THE FINAL RESULTS OF THE STUDY BE REPORTED TO THE 70TH LEGISLATURE. NOW, THEREFORE, BE IT RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA: That the Legislative Council be requested to designate an appropriate interim committee or statutory committee, pursuant to section 5-5-217, MCA, or direct sufficient staff resources to: (1) examine and review the structure of the prescription drug supply chain in the state, including: (a) pharmacies, pharmacy services administrative organizations, pharmacy benefit managers, manufacturers, providers, wholesalers, patients, and health plans; (b) the roles, relationships, and decisionmaking authority of these stakeholders within the supply chain; and (c) how those dynamics affect pharmacy operations, prescription drug affordability, and patient access, using aggregated, publicly available, or voluntarily provided data; (2) identify factors contributing to pharmacy openings, closures, and patient accessibility, including economic pressures, staffing availability, business arrangements, and geographic considerations; (3) explore targeted strategies to reduce patient costs and promote the sustainability of pharmacy operations, with particular attention to rural and underserved areas; (4) assess the methods, best practices, technologies, and policy approaches …
Sponsors
- Vinton, Sue (R, 20) · primary sponsor
- Oblander, Greg (R, 38)
Latest actions
- : (S) Filed with Secretary of State
- : (H) Signed by Speaker
- : (S) Signed by President
- : (S) Returned from Enrolling
- : (S) Sent to Enrolling
- : (H) 3rd Reading
- : (H) Scheduled for 3rd Reading
- : (H) 2nd Reading
- : (H) Scheduled for 2nd Reading
- : (H) Committee Report
Votes
- Do Concur (April 29, 2025): 99 yea, 0 nay, passed
- Do Concur (April 28, 2025): 99 yea, 1 nay, passed
- Do Pass (April 22, 2025): 50 yea, 0 nay, passed
- Do Pass (April 18, 2025): 46 yea, 0 nay, passed
Subjects: Interim Study Bills, Interim Study Resolutions, Professions and Occupations O-Z, Health Care Services, Health
Common questions
- What is SJ33?
- SJ33 is a bill in the Montana Legislature (2025 Regular Session): Interim study of the prescription drug supply chain.
- What does SJ33 do?
- In its own words: A joint resolution of the senate and the house of representatives of the state of montana requesting an interim study on the entities within the prescription drug supply chain, pharmacy sustainability, and the impacts on affordability and patient access; and requiring that the final results of the study be reported to the 70th legislature. now, therefore.
- What is the status of SJ33?
- Passed one chamber as of May 5, 2025. Latest action: (S) Filed with Secretary of State (May 5, 2025).
- Who sponsored SJ33?
- Vinton, Sue (R, 20), with 1 co-sponsor.
- Where is the official record for SJ33?
- On the Montana Legislature website: https://bills.legmt.gov/#/laws/bill/2/LC0632
Source: official Montana record. Tracked by Delilah, AI for legislation across all 50 states and Congress.